Cooper Companies Inc
NASDAQ:COO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Cooper Companies Inc
NASDAQ:COO
|
US |
|
Amte Power PLC
LSE:AMTE
|
UK |
|
Azenta Inc
NASDAQ:AZTA
|
US |
|
P
|
Publicis Groupe SA
OTC:PGPEF
|
FR |
|
V
|
Viet Nam Petroleum Transport JSC
VN:VIP
|
VN |
|
Goa Carbon Ltd
NSE:GOACARBON
|
IN |
|
FAR Ltd
ASX:FAR
|
AU |
|
B
|
BVZ Holding AG
SIX:BVZN
|
CH |
|
Elliptic Laboratories ASA
OSE:ELABS
|
NO |
|
Adairs Ltd
ASX:ADH
|
AU |
|
K
|
KMW Co Ltd
KOSDAQ:032500
|
KR |
|
Shree Rama Multi-Tech Ltd
NSE:SHREERAMA
|
IN |
|
Atrium Mortgage Investment Corp
TSX:AI
|
CA |
|
Mastercard Inc
NYSE:MA
|
US |
|
Trans Power Marine Tbk PT
IDX:TPMA
|
ID |
|
N
|
Newmont Corporation
ASX:NEM
|
US |
|
Fevertree Drinks PLC
LSE:FEVR
|
UK |
|
M
|
Myriad Genetics Inc
XETRA:MYD
|
US |
|
Hatten Land Ltd
SGX:PH0
|
SG |
|
A
|
Altshuler Shaham Financial Ltd
TASE:ALTF
|
IL |
|
Samsung Life Insurance Co Ltd
KRX:032830
|
KR |
|
Libord Finance Ltd
BSE:511593
|
IN |
|
L
|
Lubawa SA
WSE:LBW
|
PL |
|
American Electric Power Company Inc
NASDAQ:AEP
|
US |
Cooper Companies Inc
In the world of healthcare innovation, Cooper Companies Inc. etched its name as a significant player, specializing in creating products that enhance lives, particularly in the fields of vision care and women’s health. Established in 1958, Cooper Companies evolved to become a holding company operating through its two primary business units: CooperVision and CooperSurgical. CooperVision is renowned globally for its expertise in contact lenses, providing a diversified range of lenses to correct myopia, hyperopia, astigmatism, and presbyopia. By leveraging cutting-edge technology and a deep understanding of wearer needs, CooperVision caters to a wide spectrum of users, from daily disposables to specialty lenses, thus driving consistent revenue through the consumable nature of its products.
CooperSurgical, on the other hand, focuses on solutions for women’s health, offering a gamut of medical instruments, devices, and diagnostics. This unit extends Cooper Companies' footprint into the realms of fertility products, contraception, and obstetrics. By addressing key segments of the women’s health market, CooperSurgical supports clinical needs across a woman’s lifespan. Revenue opportunities here arise from both its durable medical equipment and consumable products, which ensure a stream of repeat business as healthcare providers replenish their supplies. Together, these divisions enable Cooper Companies to not only secure a robust market position but also continuously explore new areas for growth and expansion within the broader healthcare industry.
In the world of healthcare innovation, Cooper Companies Inc. etched its name as a significant player, specializing in creating products that enhance lives, particularly in the fields of vision care and women’s health. Established in 1958, Cooper Companies evolved to become a holding company operating through its two primary business units: CooperVision and CooperSurgical. CooperVision is renowned globally for its expertise in contact lenses, providing a diversified range of lenses to correct myopia, hyperopia, astigmatism, and presbyopia. By leveraging cutting-edge technology and a deep understanding of wearer needs, CooperVision caters to a wide spectrum of users, from daily disposables to specialty lenses, thus driving consistent revenue through the consumable nature of its products.
CooperSurgical, on the other hand, focuses on solutions for women’s health, offering a gamut of medical instruments, devices, and diagnostics. This unit extends Cooper Companies' footprint into the realms of fertility products, contraception, and obstetrics. By addressing key segments of the women’s health market, CooperSurgical supports clinical needs across a woman’s lifespan. Revenue opportunities here arise from both its durable medical equipment and consumable products, which ensure a stream of repeat business as healthcare providers replenish their supplies. Together, these divisions enable Cooper Companies to not only secure a robust market position but also continuously explore new areas for growth and expansion within the broader healthcare industry.
Revenue: Consolidated Q1 revenue $1.024 billion, up 6.2% year-over-year (up 2.9% organically); CooperVision $695 million, CooperSurgical $329 million.
Profitability: Q1 gross margin 68.1% and non-GAAP EPS $1.10 (up 20%); operating income improved and operating margin reached 26.9%.
Cash & capital: Q1 free cash flow $159 million with CapEx $102 million; repurchased $92 million of stock and reduced net debt to $2.4 billion.
Guide raise: Management raised EPS guidance to $4.58–$4.66 and increased fiscal 2026 free cash flow guide to $600–$625 million; revenue guidance largely unchanged at $4.30–$4.35 billion.
Demand trends: MyDay portfolio and MiSight drove strength (MiSight +23%); Americas and EMEA showing momentum, Asia Pac pressured by Japan legacy hydrogel decline but expected to recover by fiscal Q3.
Operational actions: Reorganization and IT/AI investments are delivering durable cost synergies; management is reinvesting some savings into sales/marketing and product launches.
Strategic review: Board-led strategic review is ongoing; no definitive update provided but management continues normal operations (buybacks, debt paydown, reinvestment).